Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study

被引:24
|
作者
Kanarek, Norma F. [1 ,2 ]
Kanarek, Marty S. [3 ,4 ]
Olatoye, Dare [5 ]
Carducci, Michael A. [6 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA
[2] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA
[4] Univ Wisconsin Madison, Nelson Inst Environm Studies, Madison, WI 53726 USA
[5] Johns Hopkins Sch Med, Baltimore, MD 21205 USA
[6] Johns Hopkins Sch Med, Dept Oncol Urol Oncol, Baltimore, MD USA
来源
TRIALS | 2012年 / 13卷
关键词
Justice; Beneficence; Respect for persons; Clinical trials; Clinical trial accrual; Prostate cancer; Barriers to clinical trials; Disparities; Framework; PROSTATE-SPECIFIC ANTIGEN; COMPREHENSIVE CANCER CENTER; INFORMED-CONSENT; RANDOMIZED-TRIALS; PATIENT INTEREST; DECISION-MAKING; BREAST-CANCER; WORKING GROUP; IMPACT; ENROLLMENT;
D O I
10.1186/1745-6215-13-237
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might participate given reasonable access. Methods: A hierarchical approach is utilized in measuring staged participation from trial availability to patient enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an initial six month consultation are tracked from one stage to the next by race using the framework to assess participation comparability. Results: We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45% patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%. The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial availability, patient interest and patient consented were three transitions that were below the average; none were statistically significant. Conclusions: The framework may serve to streamline comprehensive reporting of clinical trial participation to the benefit of patients and the ethical conduct of clinical trials.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] ACUTE CLINICAL OUTCOMES FOLLOWING PARTICIPATION IN SHORT-TERM CFTR MODULATOR TRIALS IN ADULTS WITH CYSTIC FIBROSIS: A RETROSPECTIVE CHART REVIEW
    Carpino, E. A.
    Fowler, R. E.
    Uluer, A. Z.
    Sawicki, G. S.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 260 - 261
  • [12] Towards a conceptual framework for addressing state-level barriers to decentralized clinical trials in the US
    Zawada, Stephanie J. J.
    Ruff, Kevin C. C.
    Sklar, Tara
    Demaerschalk, Bart M. M.
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 7 (01)
  • [13] Interpreting results of clinical trials: A conceptual framework
    Singh, Ajay K.
    Kelley, Ken
    Agarwal, Rajiv
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (05): : 1246 - 1252
  • [14] Identifying Barriers to Postpartum Tubal Ligation: A Retrospective Chart Review
    Ng, June Hoi Ka
    Esguerra, Cybill Ruth
    Ho, Diana Yau
    Patel, Jharna M.
    Amico, Jennifer
    OBSTETRICS AND GYNECOLOGY, 2019, 133 : 151S - 151S
  • [15] A Review of Barriers to Minorities' Participation in Cancer Clinical Trials: Implications for Future Cancer Research
    Salman, Ali
    Claire Nguyen
    Lee, Yi-Hui
    Cooksey-James, Tawna
    JOURNAL OF IMMIGRANT AND MINORITY HEALTH, 2016, 18 (02) : 447 - 453
  • [16] A Review of Barriers to Minorities’ Participation in Cancer Clinical Trials: Implications for Future Cancer Research
    Ali Salman
    Claire Nguyen
    Yi-Hui Lee
    Tawna Cooksey-James
    Journal of Immigrant and Minority Health, 2016, 18 : 447 - 453
  • [17] Re: Surveys identify barriers to participation in clinical trials
    Wagle, N
    Goldman, DP
    Kilgore, M
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (03) : 238 - 239
  • [18] Participation of the Elderly Population in Clinical Trials: Barriers and Solutions
    Denson, Aaron C.
    Mahipal, Amit
    CANCER CONTROL, 2014, 21 (03) : 209 - 214
  • [19] Barriers exist to patient participation in clinical trials.
    Guarino, MJ
    Masters, GA
    Schneider, CJ
    Biggs, DD
    Grubbs, SS
    Himelstein, AL
    Martin, SE
    Michaels, LM
    Guarino, AJ
    Rejtos, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 531S - 531S
  • [20] Identifying motivations and barriers to patient participation in clinical trials
    Jones, Jennifer M.
    Nyhof-Young, Joyce
    Nyhof-Young, Joyce
    Nyhof-Young, Joyce
    Moric, Jakov
    Friedman, Audrey
    Wells, Woody
    Catton, Pamela
    JOURNAL OF CANCER EDUCATION, 2006, 21 (04) : 237 - 242